AASLD 2013

infohep news

• Protease inhibitors

  Faldaprevir safe and effective in HCV treatment-experienced patients

  Michael Carter / 13 December 2013

  Triple therapy including the investigational hepatitis C virus (HCV) protease inhibitor faldaprevir is a safe and effective treatment for people who did not respond to a previous course of HCV treatment, results of ...

• Therapies

  Liver Meeting ends with hepatitis C debrief and the future of treatment

  Keith Alcorn / 11 December 2013

  The final day of The Liver Meeting 2013, the 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD) recently held in Washington, DC, featured an overview of ...

• Tenofovir alafenamide shows similar anti-hepatitis B activity with less kidney toxicity

  Liz Highleyman / 05 December 2013

  A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but ...

• Black hepatitis C patients do well on sofosbuvir oral regimens

  Liz Highleyman / 03 December 2013

  Interferon-free treatment using a single once-daily combination pill containing sofosbuvir plus ledipasvir demonstrated potent activity against hepatitis C virus (HCV)  and was generally well tolerated in a primarily African-American inner city population with ...

• Interferon-free regimens

  Faldaprevir all-oral regimen shows 100% response rate for people with HCV 1a in interim analysis

  Liz Highleyman / 02 December 2013

  An interferon-free regimen of faldaprevir, deleobuvir and PPI-668 led to a 4-week post-treatment sustained virological response (SVR4) in treatment-naive patients with hard-to-treat HCV subtype 1a in an ongoing phase 2 trial, according to ...

• Antiviral therapy

  Entecavir + tenofovir works well for people with hepatitis B who have had prior treatment failure

  Liz Highleyman / 28 November 2013

  A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated among people with chronic hepatitis B who had experienced treatment failure with ...

• Interferon-free regimens

  Daclatasvir + asunaprevir cures 85% of genotype 1b hepatitis C patients in Japanese study

  Liz Highleyman / 27 November 2013

  An interferon- and ribavirin-free oral regimen of daclatasvir plus asunaprevir taken for 24 weeks led to sustained virological response (SVR12) in 85% of Japanese patients with hepatitis C virus subtype 1b, according to ...

• HBV vaccination

  Hepatitis B vaccine protection lasts for at least 30 years

  Liz Highleyman / 21 November 2013

  Hepatitis B vaccination provides long-term protection through 30 years for a majority of recipients, and more than 90% were protected with either initial immunisation or a booster, according to a presentation at ...

• Treatment outcomes

  Successful hepatitis C treatment reduces risk of liver cancer and death, but most remain untreated

  Liz Highleyman / 19 November 2013

  Hepatitis C treatment that leads to viral cure significantly reduces the likelihood of liver disease progression and liver-related mortality, but most people with hepatitis C remain untreated, according to a presentation at The Liver ...

• Nucleotide Ns5B polymerase inhibitors

  Sofosbuvir/ribavirin for 24 weeks cures most genotype 3 hepatitis C patients, adding interferon may help difficult-to-treat

  Liz Highleyman / 14 November 2013

  A dual oral regimen of sofosbuvir plus ribavirin led to sustained response for 93% of people with genotype 2 hepatitis C treated for 12 weeks and 85% of people with genotype 3 ...